{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:34:06Z","timestamp":1788406446990,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1A3A2032927"],"award-info":[{"award-number":["2015R1A3A2032927"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1D1A1B07045491"],"award-info":[{"award-number":["2018R1D1A1B07045491"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiogenesis and synoviocyte hyperplasia, called \u2018pannus,\u2019 are pathologic hallmarks of rheumatoid arthritis (RA). To determine the clinical significance of angiogenic cytokines in RA, the levels of pro-angiogenic cytokines, including VEGF, placenta growth factor (PlGF), and IL-6, were measured in the synovial fluid (SF,<jats:italic>n<\/jats:italic>\u2009=\u200954) and sera of RA patients (<jats:italic>n<\/jats:italic>\u2009=\u2009157) using ELISA. Patients (<jats:italic>n<\/jats:italic>\u2009=\u2009103) with disease activity score 28 (DAS28)\u2009&gt;\u20093.2, which indicates moderate to high RA activity, underwent follow-up blood sampling at 6 months after treatment with conventional disease-modifying anti-rheumatic drugs (c-DMARD) or biologic DMARD (b-DMARD) including an anti-TNF\u03b1 antibody, an anti-IL-6 antibody, and abatacept. Ultrasonography (US) was performed on affected joints to define the synovitis severity at the time of sampling. Consequently, in the SF of RA patients, PlGF and IL-6 levels correlated well with synovitis severity determined by US. In RA sera, VEGF and IL-6 levels were elevated in proportion to synovitis severity, correlating with conventional markers for disease activity, including ESR, CRP, and DAS28. In c-DMARD users (<jats:italic>n<\/jats:italic>\u2009=\u200953), serially monitored levels of serum VEGF, IL-6, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) all decreased in good and moderate responders but not in nonresponders. In b-DMARD users (<jats:italic>n<\/jats:italic>\u2009=\u200949), only serum VEGF well represented the treatment response, while CRP nonspecifically decreased irrespective of the treatment outcome. By multivariable analysis, serum \u0394VEGF, but not \u0394ESR or \u0394CRP, was an independent factor associated with good and moderate responses to DMARD. In summary, the angiogenic cytokines PlGF and VEGF represent the synovitis severity of RA assessed by US. In patients receiving b-DMARD, serum VEGF may be more valuable than CRP in reflecting the treatment response.<\/jats:p>","DOI":"10.1038\/s12276-020-0443-8","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T04:02:33Z","timestamp":1590552153000},"page":"843-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in rheumatoid arthritis"],"prefix":"10.1038","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0498-5762","authenticated-orcid":false,"given":"Ji\u2010Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saseong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ah","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-1449","authenticated-orcid":false,"given":"Jung Hee","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-8496","authenticated-orcid":false,"given":"Wan-Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"443_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/art.40406","volume":"70","author":"S You","year":"2018","unstructured":"You, S., Koh, J. H., Leng, L., Kim, W. U. & Bucala, R. The tumor-like phenotype of rheumatoid synovium: molecular profiling and prospects for precision medicine. Arthritis Rheumatol. 70, 637\u2013652 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"443_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2011.04.020","volume":"10","author":"A Marrelli","year":"2011","unstructured":"Marrelli, A. et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun. Rev. 10, 595\u2013598 (2011).","journal-title":"Autoimmun. Rev."},{"key":"443_CR3","first-page":"1253","volume":"24","author":"JR Jackson","year":"1997","unstructured":"Jackson, J. R., Minton, J. A., Ho, M. L., Wei, N. & Winkler, J. D. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J. Rheumatol. 24, 1253\u20131259 (1997).","journal-title":"J. Rheumatol."},{"key":"443_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2249.1999.00775.x","volume":"115","author":"B Berse","year":"1999","unstructured":"Berse, B. et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin. Exp. Immunol. 115, 176\u2013182 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.10520","volume":"46","author":"C Hitchon","year":"2002","unstructured":"Hitchon, C. et al. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 46, 2587\u20132597 (2002).","journal-title":"Arthritis Rheum."},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/ar2689","volume":"11","author":"MA Akhavani","year":"2009","unstructured":"Akhavani, M. A. et al. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res. Ther. 11, R64 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrrheum.2011.205","volume":"8","author":"S Konisti","year":"2012","unstructured":"Konisti, S., Kiriakidis, S. & Paleolog, E. M. Hypoxia\u2013a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat. Rev. Rheumatol. 8, 153\u2013162 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/1529-0131(200009)43:9<2056::AID-ANR17>3.0.CO;2-2","volume":"43","author":"M de Bandt","year":"2000","unstructured":"de Bandt, M. et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470\/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum. 43, 2056\u20132063 (2000).","journal-title":"Arthritis Rheum."},{"key":"443_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","volume":"18","author":"N Ferrara","year":"1997","unstructured":"Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4\u201325 (1997).","journal-title":"Endocr. Rev."},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/scbi.1998.0091","volume":"9","author":"T Veikkola","year":"1999","unstructured":"Veikkola, T. & Alitalo, K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 9, 211\u2013220 (1999).","journal-title":"Semin. Cancer Biol."},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH649>3.0.CO;2-E","volume":"191","author":"M Ikeda","year":"2000","unstructured":"Ikeda, M., Hosoda, Y., Hirose, S., Okada, Y. & Ikeda, E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J. Pathol. 191, 426\u2013433 (2000).","journal-title":"J. Pathol."},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.180.1.341","volume":"180","author":"RA Fava","year":"1994","unstructured":"Fava, R. A. et al. Vascular permeability factor\/endothelial growth factor (VPF\/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180, 341\u2013346 (1994).","journal-title":"J. Exp. Med."},{"key":"443_CR13","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","volume":"152","author":"AE Koch","year":"1994","unstructured":"Koch, A. E. et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149\u20134156 (1994).","journal-title":"J. Immunol."},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1","volume":"41","author":"EM Paleolog","year":"1998","unstructured":"Paleolog, E. M. et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41, 1258\u20131265 (1998).","journal-title":"Arthritis Rheum."},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/03009749850154429","volume":"27","author":"M Harada","year":"1998","unstructured":"Harada, M. et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 27, 377\u2013380 (1998).","journal-title":"Scand. J. Rheumatol."},{"key":"443_CR16","first-page":"321","volume":"19","author":"SS Lee","year":"2001","unstructured":"Lee, S. S. et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 19, 321\u2013324 (2001).","journal-title":"Clin. Exp. Rheumatol."},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.clim.2007.04.014","volume":"124","author":"G Clavel","year":"2007","unstructured":"Clavel, G. et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin. Immunol. 124, 158\u2013164 (2007).","journal-title":"Clin. Immunol."},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3899\/jrheum.090941","volume":"37","author":"D Kurosaka","year":"2010","unstructured":"Kurosaka, D. et al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J. Rheumatol. 37, 1121\u20131128 (2010).","journal-title":"J. Rheumatol."},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.4049\/jimmunol.177.8.5727","volume":"177","author":"WU Kim","year":"2006","unstructured":"Kim, W. U. et al. Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. J. Immunol. 177, 5727\u20135735 (2006).","journal-title":"J. Immunol."},{"key":"443_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2249.2000.01097.x","volume":"119","author":"MJ Bottomley","year":"2000","unstructured":"Bottomley, M. J. et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin. Exp. Immunol. 119, 182\u2013188 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.24289","volume":"60","author":"SA Yoo","year":"2009","unstructured":"Yoo, S. A. et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum. 60, 345\u2013354 (2009).","journal-title":"Arthritis Rheum."},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.1402900","volume":"194","author":"SA Yoo","year":"2015","unstructured":"Yoo, S. A. et al. Placental growth factor-1 and -2 induce hyperplasia and invasiveness of primary rheumatoid synoviocytes. J. Immunol. 194, 2513\u20132521 (2015).","journal-title":"J. Immunol."},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41590-019-0456-4","volume":"20","author":"SA Yoo","year":"2019","unstructured":"Yoo, S. A. et al. Placental growth factor regulates the generation of TH17 cells to link angiogenesis with autoimmunity. Nat. Immunol. 20, 1348\u20131359 (2019).","journal-title":"Nat. Immunol."},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/acr.22765","volume":"68","author":"J Wang","year":"2016","unstructured":"Wang, J., Devenport, J., Low, J. M., Yu, D. & Hitraya, E. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care. Res. 68, 882\u2013885 (2016).","journal-title":"Arthritis Care. Res."},{"key":"443_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/jim-2017-000705","volume":"66","author":"WC Chiu","year":"2018","unstructured":"Chiu, W. C. et al. Ultrasound is more reliable than inflammatory parameters to evaluate disease activity in patients with RA receiving tocilizumab therapy. J. Investig. Med. 66, 1015\u20131018 (2018).","journal-title":"J. Investig. Med."},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580\u20131588 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-15-1227","volume":"75","author":"G Gopinathan","year":"2015","unstructured":"Gopinathan, G. et al. Interleukin-6 stimulates defective angiogenesis. Cancer Res. 75, 3098\u20133107 (2015).","journal-title":"Cancer Res."},{"key":"443_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/art.10877","volume":"48","author":"M Szkudlarek","year":"2003","unstructured":"Szkudlarek, M. et al. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 48, 955\u2013962 (2003).","journal-title":"Arthritis Rheum."},{"key":"443_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000428","volume":"3","author":"MA D\u2019Agostino","year":"2017","unstructured":"D\u2019Agostino, M. A. et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open 3, e000428 (2017).","journal-title":"RMD Open"},{"key":"443_CR30","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde, D. How to read radiographs according to the Sharp\/van der Heijde method. J. Rheumatol. 27, 261\u2013263 (2000).","journal-title":"J. Rheumatol."},{"key":"443_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson, J. et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care. Res. 64, 640\u2013647 (2012).","journal-title":"Arthritis Care. Res."},{"key":"443_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen, J. & van Riel, P. L. The disease activity score and the EULAR response criteria. Rheum. Dis. Clin. North. Am. 35, 745\u2013757, vii-viii (2009).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"443_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.1780310614","volume":"31","author":"FA Houssiau","year":"1988","unstructured":"Houssiau, F. A., Devogelaer, J. P., Van Damme, J., de Deuxchaisnes, C. N. & Van Snick, J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31, 784\u2013788 (1988).","journal-title":"Arthritis Rheum."},{"key":"443_CR34","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0024-3205(01)01264-4","volume":"69","author":"H Sone","year":"2001","unstructured":"Sone, H. et al. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life. Sci. 69, 1861\u20131869 (2001).","journal-title":"Life. Sci."},{"key":"443_CR35","doi-asserted-by":"publisher","unstructured":"Rajaei, E. et al. Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity. Curr. Rheumatol. Rev. https:\/\/doi.org\/10.2174\/1573397115666190206144223 (2019).","DOI":"10.2174\/1573397115666190206144223"},{"key":"443_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/annrheumdis-2012-202669","volume":"73","author":"M Andersen","year":"2014","unstructured":"Andersen, M. et al. Ultrasound colour Doppler is associated with synovial pathology in biopsies from hand joints in rheumatoid arthritis patients: a cross-sectional study. Ann. Rheum. Dis. 73, 678\u2013683 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/ard.61.1.55","volume":"61","author":"M Hau","year":"2002","unstructured":"Hau, M. et al. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). Ann. Rheum. Dis. 61, 55\u201358 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/ard.62.2.178","volume":"62","author":"L Terslev","year":"2003","unstructured":"Terslev, L. et al. Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann. Rheum. Dis. 62, 178\u2013181 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR39","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/art.23682","volume":"58","author":"E Naredo","year":"2008","unstructured":"Naredo, E., Moller, I., Cruz, A., Carmona, L. & Garrido, J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum. 58, 2248\u20132256 (2008).","journal-title":"Arthritis Rheum."},{"key":"443_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.33312","volume":"64","author":"V Foltz","year":"2012","unstructured":"Foltz, V. et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum. 64, 67\u201376 (2012).","journal-title":"Arthritis Rheum."},{"key":"443_CR41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/rheumatology\/kep171","volume":"48","author":"CA Scire","year":"2009","unstructured":"Scire, C. A. et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 48, 1092\u20131097 (2009).","journal-title":"Rheumatology"},{"key":"443_CR42","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2011-200548","volume":"71","author":"B Saleem","year":"2012","unstructured":"Saleem, B. et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann. Rheum. Dis. 71, 1316\u20131321 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR43","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/rheumatology\/keq415","volume":"50","author":"SY Kawashiri","year":"2011","unstructured":"Kawashiri, S. Y. et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatology 50, 962\u2013965 (2011).","journal-title":"Rheumatology"},{"key":"443_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/rheumatology\/keu354","volume":"54","author":"J Kitchen","year":"2015","unstructured":"Kitchen, J. & Kane, D. Greyscale and power Doppler ultrasonographic evaluation of normal synovial joints: correlation with pro- and anti-inflammatory cytokines and angiogenic factors. Rheumatology 54, 458\u2013462 (2015).","journal-title":"Rheumatology"},{"key":"443_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/ard.2007.069690","volume":"67","author":"G Wells","year":"2008","unstructured":"Wells, G., Li, T., Maxwell, L., Maclean, R. & Tugwell, P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann. Rheum. Dis. 67, 260\u2013265 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"443_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/bmj.2.5544.85","volume":"2","author":"LE Bottiger","year":"1967","unstructured":"Bottiger, L. E. & Svedberg, C. A. Normal erythrocyte sedimentation rate and age. Br. Med. J. 2, 85\u201387 (1967).","journal-title":"Br. Med. J."},{"key":"443_CR48","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/art.1780340819","volume":"34","author":"I Kushner","year":"1991","unstructured":"Kushner, I. C-reactive protein in rheumatology. Arthritis Rheum. 34, 1065\u20131068 (1991).","journal-title":"Arthritis Rheum."},{"key":"443_CR49","first-page":"S\u20131","volume":"32","author":"T Pincus","year":"2014","unstructured":"Pincus, T., Braun, J., Kavanaugh, A. & Smolen, J. S. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care. Clin. Exp. Rheumatol. 32, S\u20131 (2014).","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-0443-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-0443-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-0443-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T14:41:14Z","timestamp":1696171274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-0443-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1038\/s12276-020-0443-8","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"26 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}